Moolec Science SA (NASDAQ:MLEC) shares are down on Wednesday. On Tuesday, the company announced a significant breakthrough in molecular farming.



Moolec said it successfully demonstrated the stable expression of bovine myoglobin in pea seeds, expanding its molecular farming platform, which could enhance its market position in the alternative protein sector.



Moolec Science has achieved a milestone by producing bovine myoglobin in pea seeds through a 28-month research project with a leading U.S. academic institution. 



This breakthrough reinforces the company’s ability to expand its molecular farming capabilities and could unlock new pathways for scalable protein production.



<h2>Technical Analysis</h2>



At $10.80, the stock is trading 28.1% above its 20-day simple moving average (SMA) and 21.8% above its 50-day SMA, suggesting a bullish short-term trend. However, it is trading 49.7% below its 200-day SMA, indicating a bearish long-term trend that traders should monitor closely.



The relative strength index (RSI) is currently at 58.88, suggesting that the stock is in neutral territory, with no immediate overbought or oversold conditions. This positioning indicates that there may be room for upward movement if buying interest increases.



<ul>
<li>Key Resistance: $12.50 — This level could act as a barrier for upward price movement.</li>
</ul>



The stock has experienced a significant 12-month decline of 89.07%, reflecting ongoing challenges in maintaining investor confidence. Currently, it is trading near the middle of its 52-week range, which suggests a lack of strong momentum in either direction.



Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through molecular farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system.



The recent breakthrough in expressing bovine myoglobin in pea seeds not only validates Moolec’s innovative approach but also positions the company to capitalize on the growing demand for sustainable protein sources. With a diversified pipeline that includes various products, Moolec is well-placed to impact the food industry significantly.



<h2>Earnings</h2>



The countdown is on: Moolec Science SA Ordinary Shares is set to report earnings on April 20, 2026 (estimated).



<ul>
<li>EPS Estimate: 900 cents (Down from 1000 cents)</li>



<li>Revenue Estimate: $2.64 Million (Down from $3.00 Million)</li>
</ul>



<h2>Benzinga Edge Rankings</h2>



Below is the Benzinga Edge scorecard for Moolec Science SA Ordinary Shares, highlighting its strengths and weaknesses compared to the broader market:



<ul>
<li>Momentum: Strong (Score: 80.93) — Stock is outperforming the broader market.</li>
</ul>



The Verdict: Moolec Science SA Ordinary Shares’s Benzinga Edge signal reveals a momentum-driven story, suggesting potential for growth as the company advances its innovative projects in the alternative protein sector.



MLEC Price Action: Moolec Science shares were down 10.01% at $9.80 at the time of publication on Wednesday. The stock is near its 52-week low of $3.07, according to Benzinga Pro data.



Image via Shutterstock/ Gorodenkoff

Moolec Science shares fell 10.01% to $9.80 despite a breakthrough in producing bovine myoglobin in pea seeds. The company's innovation, achieved through a 28-month research project, enhances its position in the alternative protein sector. However, weak long-term trends and a significant 12-month decline of 89.07% overshadowed this progress. The stock is trading 28.1% above its 20-day SMA but 49.7% below its 200-day SMA, indicating mixed signals. Moolec is set to report earnings on April 20, 2026, with revised EPS and revenue estimates.

benzinga_article

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco DB Agriculture FD ETF

First Trust Indxx Global Agri

VanEck Agribusiness ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

MOOLEC SCIENCE SA C/WTS 30/01/2028(TO PUR COM)

First Trust NYSE Arca Biotech Index Fd

Moolec Science SA

What's Going On With Moolec Stock Today?